Combined SSRI plus tetracyclic antidepressant use
Initiation of sertraline and mirtazapine together is not listed as an absolute contraindication. [1] Serotonergic adverse effects remain a key safety consideration because both agents increase serotonergic activity, and serotonin syndrome has been reported with combinations of serotonergic drugs. [2][3]
Contraindications and key “do not start” conditions
Sertraline should not be used with monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue. [2] Sertraline use is also contraindicated with known hypersensitivity to sertraline. [2]
Mirtazapine should not be used with MAOIs or within 14 days of stopping an MAOI. [3] Mirtazapine is also contraindicated with known hypersensitivity to mirtazapine. [3]
Both medications require assessment for bipolar disorder risk before starting an antidepressant because antidepressant-associated mania or hypomania can occur. [2][3]
Recommended starting doses
Sertraline: adult starting dose is 50 mg once daily for indications that use the adult table in the FDA label (MDD, OCD, PD, PTSD, SAD). [2]
Mirtazapine: adult starting dose is 15 mg once daily, administered orally preferably in the evening prior to sleep. [3]
Monitoring for safety adverse effects
Close monitoring is recommended for suicidality and clinical worsening during antidepressant initiation and during dosage changes. [1][2][3]
Serotonin syndrome monitoring is recommended after initiation and after dosage increases. [2][3] Serotonin syndrome features to monitor include mental status changes, autonomic instability, neuromuscular abnormalities, seizures, and gastrointestinal symptoms. [2][3]
Hyponatremia monitoring is recommended in higher-risk groups because hyponatremia has been reported with SSRIs and with mirtazapine and can present with headache, confusion, weakness, unsteadiness, and falls. [2][3] In symptomatic hyponatremia, discontinuation of the offending antidepressant and medical intervention are recommended in the drug labeling. [2][3]
Agranulocytosis monitoring is recommended by patient symptom surveillance because mirtazapine labeling describes discontinuation and close monitoring for sore throat, fever, stomatitis, or signs of infection with low white blood cell count. [3]
Mania or hypomania emergence should be monitored because both labels include bipolar screening prior to initiation and warn about activation. [2][3]
Bleeding risk monitoring is recommended when sertraline is combined with antiplatelet agents or anticoagulants because serotonin reuptake inhibition can increase bleeding risk. [2]
Electrocardiographic risk monitoring is not routinely mandated in the labels, but caution with QT-prolonging risk is recommended when QTc-prolonging drugs or relevant cardiac risk factors are present, because both labels include QTc prolongation warnings and interaction considerations. [2][3]
If warfarin is used concurrently with mirtazapine, INR monitoring is recommended. [3]
Timing and intensity of follow-up during initiation
A treatment review is recommended within 2 weeks after starting antidepressant medication to check symptom improvement and side effects. [1] An earlier review (within 1 week) is recommended for adults aged 18 to 25 years or when there is particular concern about suicide risk. [1]
Practical starting approach when both are initiated concurrently
Concurrent initiation increases the side-effect burden and therefore supports careful adverse-effect monitoring during the early treatment period. [1] The monitoring set should prioritize suicidality, serotonin syndrome symptoms, activation of mania or hypomania, and hyponatremia symptoms in patients with elevated baseline risk. [1][2][3]
Common monitoring omissions to avoid
Routine ECG or electrolyte testing is not mandated for all patients in labeling, but hyponatremia symptom monitoring and targeted sodium testing should be emphasized for elderly patients, patients taking diuretics, and patients who are volume-depleted because these groups are identified as higher risk in the antidepressant labeling. [2][3] INR monitoring omission is a safety risk when warfarin is co-prescribed with mirtazapine. [3]